NewsEarningsCORONA Remedies Limited Reports Strong Q2 FY26 Performance with 15.1% Revenue GrowthCORONA Remedies Limited Reports Strong Q2 FY26 Performance with 15.1% Revenue Growth
CORONA Remedies Limited reported strong Q2 FY26 results with 15.1% revenue growth to ₹361.1 crores and 21.8% PAT growth to ₹52.3 crores. H1 FY26 performance was even stronger with 17% revenue growth and 35.1% PAT growth. The company acquired seven brands from Bayer Zydus for ₹7.5-8 crores and targets 15% revenue CAGR and 20% PAT growth over the next three to four years.
*this image is generated using AI for illustrative purposes only.
CORONA Remedies Limited delivered robust financial performance in Q2 FY26, marking a strong start following its stock exchange listing in December 2025. The pharmaceutical company reported significant growth across key financial metrics during its maiden earnings conference call held on January 5, 2026.
Strong Financial Performance in Q2 FY26
The company's quarterly results demonstrated solid momentum across all major financial parameters:
| Metric: | Q2 FY26 | Q2 FY25 | Growth (%) |
|---|---|---|---|
| Revenue: | ₹361.1 cr | ₹313.7 cr | +15.1% |
| EBITDA: | ₹78.5 cr | ₹66.9 cr | +17.4% |
| EBITDA Margin: | 21.7% | 21.3% | +40 bps |
| Profit After Tax: | ₹52.3 cr | ₹43.0 cr | +21.8% |
India business continued to dominate the revenue mix, contributing 96.5% of total revenue during the quarter. The company's focus on chronic and semi-chronic segments, which account for approximately 70% of total revenues, supported the healthy volume growth trajectory.
Impressive Half-Year Results
The H1 FY26 performance further reinforced the company's strong operational execution:
| Parameter: | H1 FY26 | H1 FY25 | Growth (%) |
|---|---|---|---|
| Revenue: | ₹707.7 cr | ₹605.0 cr | +17.0% |
| EBITDA: | ₹148.3 cr | ₹116.4 cr | +27.4% |
| EBITDA Margin: | 20.9% | 19.2% | +170 bps |
| Profit After Tax: | ₹98.5 cr | ₹72.9 cr | +35.1% |
The company maintained excellent operational efficiency with annualized ROE of 31.1% and ROCE of 49.7% for H1 FY26. The OCF to EBITDA conversion stood at a healthy 76.5%, while net working capital days remained at best-in-class levels of 23 days.
Strategic Brand Acquisition from Bayer Zydus
In July 2025, CORONA acquired seven brand trademarks from Bayer Zydus Pharma for approximately ₹7.5-8 crores. The acquisition includes:
- Anti-platelet segment: Noklot and Noklot CV (entering ₹1,500+ crores market)
- Infertility products: Fostine, Menodac, and Ovidac
- Women's healthcare: Spye, Vageston, and Luprofact
The company plans to launch a specialized team of less than 50 people across India to focus exclusively on infertility specialists within the next few months. This strategic move will strengthen CORONA's position in women's healthcare by adding core infertility products to its existing portfolio spanning menarche to menopause.
Manufacturing and R&D Capabilities
CORONA operates two WHO GMP certified manufacturing facilities in Gujarat and Himachal Pradesh, with the Gujarat facility also holding EU GMP certification. The company recently commissioned additional capacity of 400 million tablets and capsules at its Gujarat facility in December 2025, bringing total installed annual capacity to 1.65 billion tablets or capsules, 20 million sachets, and 10 million bottles.
The company maintains R&D centers at both manufacturing facilities, approved by the Department of Scientific and Industrial Research, with over 100 scientists currently working on product development and validation.
Growth Strategy and Future Outlook
Management outlined ambitious growth targets for the next three to four years:
- Revenue growth: 15% CAGR
- PAT/EPS growth: 20% annually
- Field force expansion: 5-7% annually from current base of 2,600+ medical representatives
The company plans to expand into additional therapeutic areas including infertility, spine, rheumatoid, CNS, dermatology, and gastrointestinal segments. CORONA currently covers approximately one-third of the Indian pharmaceutical market, providing significant opportunity for expansion.
For international business, the company is developing complex generic female hormonal products through its backward integration facility La Chandra Pharma Lab. The new hormonal plant is expected to commence commercial operations by end of Q2 or early Q3 FY27, with WHO approval targeted by Q4 FY27.
CORONA Remedies continues to demonstrate strong execution of its middle-of-pyramid strategy, focusing on specialist and super-specialist prescribers across urban and semi-urban markets while maintaining healthy financial metrics and cash flow generation.
19
